GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

The viral illness kills more people in the city than HIV, but antiviral medications may be helping cut its transmission.

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease.

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

and HBV DNA after 24 weeks' treatment to below the lower limit of detection in people with chronic hepatitis B, raising hopes that it could offer permanent cure, allowing safe termination of ...

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...

A population-based, retrospective cohort study examining the risk of HCC and mortality in 1096 treated and 1096 matched untreated HCV/HBV dually infected patients. CI, confidence interval ...

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

Major investors are betting that a Durham company has a potential cure for hepatitis B. STORY HIGHLIGHTS Tune Therapeutics raised $175 million for disease treatment development. The funding ...

A multicenter, prospective observational study of chemotherapy in elderly patients with biliary tract cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium.